Is There a Stage 5 Cancer? How Cancer Staging Works

There is no stage 5 in the standard cancer staging system used by oncologists worldwide. The most widely used framework tops out at stage IV, which describes cancer that has spread from its original site to distant organs. The one notable exception is a childhood kidney cancer called Wilms tumor, which does recognize a stage V for a specific reason. Understanding why the system stops at four, what stage IV actually tells you, and where the whole framework is headed gives a much clearer picture than the number alone.

How the Standard Staging System Works

Most solid-tumor cancers are staged using a system maintained by the American Joint Committee on Cancer (AJCC). It assigns a stage from 0 through IV based on three factors: the size and extent of the primary tumor, whether cancer cells have reached nearby lymph nodes, and whether the cancer has spread (metastasized) to distant parts of the body. Those three factors are often abbreviated as T, N, and M. A pathologist and oncologist combine the T, N, and M findings to assign an overall stage grouping.

Stage 0 refers to abnormal cells that have not yet invaded surrounding tissue. Stage I typically means a small, localized tumor. Stages II and III describe progressively larger tumors or more extensive lymph node involvement, though the exact thresholds differ by cancer type. Stage IV means the cancer has been found in at least one organ or tissue far from where it started. Once distant metastasis is confirmed, the disease is classified as stage IV regardless of the primary tumor’s size.

Because the defining feature of stage IV is distant spread, there is no logical “stage V” in this framework. The system describes how far cancer has traveled. Once it has reached distant sites, it has reached the endpoint the staging system was designed to capture. Adding another stage would require a qualitative distinction beyond “distant spread,” and the current system does not make one.

The One Cancer That Actually Has a Stage V

Wilms tumor, a kidney cancer that overwhelmingly affects young children, is the well-known exception. It uses its own staging system developed through the Children’s Oncology Group rather than the AJCC’s TNM framework. In this system, stages I through IV describe how far the tumor has spread from one kidney. Stage V is reserved for one specific situation: when tumor is found in both kidneys at the same time. Roughly 5 to 7 percent of Wilms tumor patients present with bilateral disease, either at the same time or one kidney after the other.¹ The stage V designation exists because treating tumors in both kidneys simultaneously poses distinct surgical and medical challenges that do not arise with unilateral disease.

This is not a matter of severity beyond stage IV. It is a separate clinical scenario that warranted its own category in a system designed specifically for this cancer. No other cancer in standard use has a stage V, and when people search for “stage 5 cancer,” they are almost never asking about Wilms tumor.

Not Every Cancer Uses the Same Staging Framework

The TNM system covers most solid tumors, but several major cancer types follow entirely different classification schemes. Blood cancers like leukemia and lymphoma do not form a single solid mass that grows and spreads in the way the TNM model describes. Lymphomas use systems based on how many lymph node regions are involved and whether the disease has crossed the diaphragm or entered organs outside the lymphatic system. Leukemias are often classified by cell type and genetic features rather than a stage number at all.

Brain and spinal cord tumors follow yet another path. The World Health Organization classifies central nervous system tumors primarily by their cellular and molecular characteristics, assigning grades that reflect how aggressive the cells look and behave rather than how far they have traveled.² A grade 4 brain tumor is not the same thing as a stage IV cancer in the TNM sense. The grading system tells you about the tumor’s biology, not its geography.

Testicular cancer uses the standard staging numbers but leans heavily on blood markers to fill in prognostic detail. Levels of certain proteins in the blood play crucial roles in diagnosis, staging, monitoring treatment response, and long-term surveillance.³ Two patients with the same anatomic stage can have very different expected outcomes depending on their marker levels. The point is that “what stage is it” is a less complete question than many people assume. The number is one piece of a larger puzzle that varies by cancer type.

Stage IV Does Not Mean Identical Outcomes

One reason people sometimes search for a stage 5 is that stage IV feels like it should have sub-levels. And in a sense, it does. Stage IV encompasses a vast range of clinical situations: a person with a single small metastasis in the liver that can be surgically removed, and a person with widespread disease in multiple organs. Both are stage IV, but their prognoses and treatment options can be radically different.

In stage IV melanoma, for instance, selected patients who undergo repeated surgical removal of metastases can achieve long-term survival with good quality of life.⁴ That outcome is not what most people picture when they hear “stage IV.” Many cancers now subdivide stage IV into IVA, IVB, and sometimes IVC to capture some of this variation, distinguishing between limited and extensive distant spread. But even those subdivisions cannot capture the full spectrum of what stage IV looks like in practice.

This is part of why a stage number alone never tells the whole story. Two people with stage IVA lung cancer may respond completely differently to the same treatment based on the genetic mutations driving their tumors, their overall health, and how their immune systems interact with the cancer. The staging system was built to describe anatomy, and anatomy is only one dimension of cancer.

Stage IV Versus “Terminal” or “End-Stage”

Stage IV is a medical classification based on how far the cancer has spread at diagnosis. “Terminal” and “end-stage” are not staging terms at all. They describe a clinical judgment that the disease is no longer responding to treatment and that the person’s remaining life expectancy is short. Many stage IV cancers are treatable for years, sometimes decades, particularly with modern immunotherapy and targeted drug approaches. A stage IV diagnosis does not automatically mean someone is dying soon.

Conversely, a lower-stage cancer can become terminal if it proves resistant to all available treatments. End-of-life care decisions are driven by a patient’s functional status, symptom burden, and treatment response, not by a stage number. In hospice settings, patients often have a life expectancy measured in months, and the focus shifts from fighting the disease to managing symptoms and quality of life.⁵ That transition can happen at any stage, though it is more common with advanced disease.

The confusion between “stage IV” and “terminal” is one of the most persistent misconceptions in cancer communication. When someone is told they have stage IV cancer, they often hear a death sentence. What the oncologist is actually saying is that the cancer has reached distant organs, which narrows treatment options and generally worsens the statistical outlook, but does not by itself determine how much time someone has left.

How Molecular Biology Changed Staging

For most of the history of cancer staging, the system was purely anatomic. How big is the tumor? Has it reached lymph nodes? Has it spread to other organs? Those three questions drove everything. But clinicians noticed something that the anatomy-only approach could not explain: patients with seemingly identical stages often had dramatically different outcomes. Two people with the same-size breast tumor, the same lymph node involvement, and no distant spread might see one go into lasting remission and the other relapse within a year.

The reason turned out to be molecular. Tumors that look the same under a microscope and occupy the same anatomic territory can be driven by entirely different biological machinery. Recognizing this, the AJCC’s eighth edition staging manual, adopted in 2018, began integrating molecular markers alongside anatomic findings for certain cancers. Breast cancer staging now incorporates tumor grade along with biomarker data on hormone receptor status, a growth-promoting protein called HER2, and gene expression profiling to assign a prognostic stage.⁶ This means a tumor’s biology can actually move its prognostic stage up or down relative to what anatomy alone would predict.

The broader vision behind this shift is to move from a one-size-fits-all system toward something more personalized. The AJCC’s editorial board has described the eighth edition as an effort to build a bridge from population-based staging to a more individualized approach, forming the foundation for cancer classification in the era of precision oncology.⁷ Not every cancer type has made this leap yet. For many solid tumors, staging still rests primarily on anatomy. But the direction is clear: the stage number you receive increasingly reflects your cancer’s biology, not just its geography.

Restaging After Treatment

A common source of confusion is what happens to a cancer’s stage after treatment. If someone is diagnosed at stage III, receives chemotherapy that shrinks the tumor, and then has surgery, is the cancer now stage I? Not exactly. The original stage at diagnosis stays with the patient permanently. It does not get revised downward because treatment worked.

However, doctors do assess the tumor’s extent after treatment, particularly when chemotherapy or radiation is given before surgery (a strategy called neoadjuvant therapy). The post-treatment stage is denoted with a lowercase “y” prefix to distinguish it from the original diagnosis.⁸ So a patient might carry both a clinical stage assigned at diagnosis and a pathologic stage with the “y” prefix assigned after surgery. The two numbers serve different purposes: the original stage guides prognosis based on what the cancer looked like at presentation, while the post-treatment stage helps oncologists judge how well the treatment worked and what to do next.

If cancer returns after being in remission, it is generally still referred to by its original stage. A breast cancer originally staged at II that later metastasizes to the bones is typically called “stage II breast cancer with metastatic recurrence,” not newly staged as stage IV. This can be confusing, because the disease is now behaving like stage IV cancer, but restaging from scratch is not standard practice. The conventions vary somewhat between institutions and cancer types, and this is an area where the staging system’s limitations become apparent.

How Staging Gets Determined

Staging is not a single test. It is an accumulation of information from physical exams, imaging, biopsies, blood work, and sometimes surgical findings. The process often starts with imaging to see how large the primary tumor is and whether there are signs of spread. CT scans, MRIs, and PET scans each play different roles depending on the cancer type.

PET scans combined with CT are particularly valuable when looking for distant metastases. In newly diagnosed breast cancer, for example, this combined scan has been shown to change the assigned stage and alter the treatment approach because of its ability to detect metastases in lymph nodes and distant organs that other imaging might miss.⁹ The distinction between clinical staging (based on imaging and physical exam before surgery) and pathological staging (based on what the surgeon and pathologist find during and after an operation) is significant. Pathological staging is generally more accurate because it involves direct examination of tissue, but it requires surgery to obtain.

This means two patients with the same cancer might receive different staging information depending on what tests they had access to and whether they had surgery early. A cancer that looks like stage II on imaging might turn out to be stage III once a pathologist examines the lymph nodes removed during surgery. The staging system works only as well as the tools used to gather data for it.

When Access to Staging Tools Is Unequal

Staging accuracy depends on having the right equipment and trained people to operate it. That is not a given everywhere. The global cancer burden is rising, and morbidity and mortality fall disproportionately on low- and middle-income countries, where imaging access remains poor due to insufficient equipment, shortages of trained personnel, limited interventional services, and socioeconomic constraints.¹⁰

This matters because inaccurate staging leads to mismatched treatment. A patient whose cancer has actually spread to distant sites but who cannot get a PET scan may be staged lower than the disease warrants, leading to less aggressive treatment than they need. Conversely, a patient who is over-staged might receive unnecessarily harsh treatment. Staging is only useful if the underlying diagnostic workup is thorough enough to get it right, and that thoroughness is unevenly distributed around the world.

Where Staging Is Headed

The integration of molecular markers into breast cancer staging, described earlier, is a preview of broader changes likely coming for other cancer types. As more tumors get profiled for their genetic mutations, protein expression, and other biological features, the pure anatomy-based stage number will carry less weight in treatment decisions. Some oncologists already rely more heavily on genomic test results than on the traditional stage when choosing a treatment plan for certain cancers.

A newer area of research involves liquid biopsies, which analyze fragments of tumor DNA and other molecules circulating in the blood. Artificial intelligence is being applied to these high-dimensional datasets to identify patterns that reflect tumor burden, mutational status, and disease progression, often with greater sensitivity than traditional statistical methods can achieve.¹¹ If these approaches mature into routine clinical use, staging could eventually become a more dynamic, continuously updated process rather than a snapshot taken at diagnosis. Instead of receiving a fixed stage number that stays with you forever, future patients might have their disease status tracked in something closer to real time through periodic blood draws.

None of this eliminates the need for a shared classification system. Doctors, researchers, and patients all benefit from a common language that describes how advanced a cancer is. But the contents of that language are shifting. The question “what stage is it” will likely mean something richer and more nuanced in ten years than it does today, incorporating biology, imaging, and blood-based markers into a single, more informative picture.